INBX · Inhibrx Biosciences, Inc. · Documents

Track INBX — free

$87.75 -2.85 (-3.14%) At close · Nov 12

Russell 2000 member Rebalance outlook locked

Market Cap

$1.29B

Shares

14.72M

Volume · Nov 12 226.49K Avg daily vol (3M) 305.28K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.3M up 550.0% 10-K filed Mar 19, 2026 Quarterly report FY2026 Q2 Revenue $0 10-Q filed Aug 13, 2026 Latest results Financial results 8-K filed Aug 13, 2026

2026

Sep 28

Current report 8-K

Regulation FD disclosure

Inhibrx Biosciences reported ozekibart’s chondrosarcoma registrational trial met its primary endpoint, with median PFS of 5.52 months versus 2.66 months for placebo and a 52% reduction in progression or death risk and plans FDA meeting on 1L CRC registrational trial.

Sep 8

Current report 8-K

Regulation FD disclosure, Other events AI summary on its way

Aug 13

Current report 8-K

Financial results AI summary on its way

Aug 13

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $0 Net loss $36.65M Diluted EPS -$2.34

Jul 16

Current report 8-K Events of Jul 15

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Regulation FD disclosure AI summary on its way

Jun 15

Current report 8-K

Regulation FD disclosure, Other events AI summary on its way

Jun 3

Current report 8-K

Shareholder vote results AI summary on its way

May 14

Current report 8-K

Financial results AI summary on its way

May 14

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Net loss $33.44M Diluted EPS -$2.15

May 11

Current report 8-K

Regulation FD disclosure, Other events AI summary on its way

Apr 23

Proxy statement DEF 14A

Proxy statement AI summary on its way

Apr 23

Annual report to holders ARS

Annual report to holders AI summary on its way

Apr 23

Proxy statement DEFA14A

Proxy statement AI summary on its way

Apr 21

Current report 8-K

Regulation FD disclosure, Other events AI summary on its way

Mar 19

Current report 8-K

Financial results AI summary on its way

Mar 19

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Revenue $1.3M ▲ 550.0% Net loss $140.06M Diluted EPS -$9.04

Feb 23

Current report 8-K

Regulation FD disclosure AI summary on its way

2025

Dec 16

Current report 8-K

Regulation FD disclosure, Other events

Nov 14

Current report 8-K

Financial results

Nov 14

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Revenue $0 Net loss $35.26M Diluted EPS -$2.28

Oct 23

Current report 8-K

Regulation FD disclosure, Other events

Aug 13

Current report 8-K

Financial results

Aug 13

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Revenue $1.3M ▲ 1200.0% Net loss $28.65M Diluted EPS -$1.85

May 28

Current report 8-K

Shareholder vote results

May 14

Current report 8-K

Financial results

May 14

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $0 Net loss $43.31M Diluted EPS -$2.80

Apr 17

Annual report to holders ARS

Annual report to holders

Apr 16

Proxy statement DEF 14A

Proxy statement

Apr 16

Proxy statement DEFA14A

Proxy statement

Apr 1

Current report 8-K Events of Mar 31

Director or officer change, or executive pay

Mar 17

Current report 8-K

Financial results

Mar 17

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $200K ▼ 88.9% Net income $1.69B Diluted EPS $112.62

Jan 21

Current report 8-K

Regulation FD disclosure, Other events

Jan 13

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Regulation FD disclosure

2024

Nov 14

Current report 8-K

Financial results

Nov 14

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $0 Net loss $43.86M Diluted EPS -$2.84

Nov 4

Current report 8-K

Other events

Aug 13

Current report 8-K

Financial results, Regulation FD disclosure

Aug 13

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $100K ▲ 233.3% Net income $1.86B Diluted EPS $125.48

Jun 17

Current report 8-K

Regulation FD disclosure

Jun 11

Registration statement S-1

Registration statement

May 30

Current report 8-K Events of May 29

Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights, Change in control, Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Other events

May 24

Current report 8-K

Regulation FD disclosure

Showing 1–43 of 43 documents

Key facts CIK 2007919 CUSIP 45720N103 13F (30d) 88 filings 84 filers Visit website Investor relations